High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
- PMID: 32683272
- PMCID: PMC7334969
- DOI: 10.1016/j.ejca.2020.06.026
High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
Conflict of interest statement
Conflict of interest statement U.D.G. reports receiving advisory board or consultant fees from Merck Sharp & Dohme, Bristol Myers Squibb, Janssen, Astellas, Sanofi, Bayer, Pfizer, Ipsen, Novartis and PharmaMar and institutional research grant from AstraZeneca, Sanofi andRoche. The other authors declare no conflicts of interest.
Comment on
-
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14. Lancet Oncol. 2020. PMID: 32066541 Free PMC article. No abstract available.
References
-
- Einhorn L.H., Williams S.D., Chamness A., Brames M.J., Perkins S.M., Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–348. - PubMed
-
- International Germ Cell Cancer Collaborative Group International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603. - PubMed
-
- U.S. Food & Drug administration: Emergency use authorizations. https://www.fda.gov/medicaldevices/emergency-situations-medical-devices/....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical